Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SD-101 via hepatic artery infusion with checkpoint inhibitors in metastatic uveal melanoma
NCT04935229Phase 1Terminated
- Sponsor
- TriSalus Life Sciences
- Start
- Aug 2021
- Primary completion
- Jul 2024
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of nelitolimod in Uveal melanoma (UM) (6 cohorts), sponsored by TriSalus Life Sciences. Primary endpoints: Safety of SD-101 Alone and in Combination at 12 months, Maximum Tolerable Dose or Optimal Dose at 12 months and 2 more. Started Aug 2021; status: terminated.
02
Drugs
nelitolimod
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04935229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935229.